Non Squamous Non Small Cell Lung Cancer Nsclc clinical trials

Explore recruiting non squamous non small cell lung cancer nsclc clinical trials.

Recruiting non squamous non small cell lung cancer nsclc studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Non Squamous Non Small Cell Lung Cancer Nsclc trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase III randomised, double-blind, multicentre study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB27 (proposed pembrolizumab biosimilar) and Keytruda in subjects with metastatic non-squamous non-small cell lung cancer

Spain, Romania, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

Phase 2, Open-Label Study in Subjects with Previously Untreated MET Amplified Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Romania, Germany, Italy, France, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study of Tiragolumab in combination with Atezolizumab plus Pemetrexed and Carboplatin/Cisplatin versus Pembrolizumab plus Pemetrexed and Carboplatin/Cisplatin in Patients with previously Untreated Advanced Non-Squamous Non-Small-Cell Lung Cancer

Spain, France, Denmark, Belgium, Germany, Poland

Phase II and Phase III (Integrated) EU CTIS Study details

A Multicenter, Randomized, Double-blind Trial to Demonstrate Similar Efficacy, Safety, and Immunogenicity of FYB206 (Keytruda Biosimilar Candidate) in Comparison to Keytruda (Pembrolizumab) as an Add-on to Chemotherapy in Treatment-naïve Patients with Metastatic Non-squamous Non-small Cell Lung Cancer (LOTUS)

Romania, Bulgaria, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2, Randomized, Blinded, Placebo-Controlled Trial Investigating the Efficacy and Safety of Visugromab versus Placebo, in Combination with Pembrolizumab, Pemetrexed, and Carboplatin, in First-Line Treatment of Participants with Metastatic Non-Squamous Non-Small Cell Lung Cancer (GDFATHER-NSCLC-01)

Bulgaria, Spain, Romania, Poland, Germany, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase 1b/2a safety and tolerability study of bemcentinib with pembrolizumab/carboplatin/pemetrexed in subjects with untreated advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) without/with a STK11 mutation.

France, Italy, Greece, Poland, Spain, Hungary

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Non Squamous Non Small Cell Lung Cancer Nsclc trials by city

Non Squamous Non Small Cell Lung Cancer Nsclc in Toronto Non Squamous Non Small Cell Lung Cancer Nsclc in Vancouver Non Squamous Non Small Cell Lung Cancer Nsclc in Montreal Non Squamous Non Small Cell Lung Cancer Nsclc in Calgary Non Squamous Non Small Cell Lung Cancer Nsclc in Edmonton Non Squamous Non Small Cell Lung Cancer Nsclc in Ottawa Non Squamous Non Small Cell Lung Cancer Nsclc in Winnipeg Non Squamous Non Small Cell Lung Cancer Nsclc in Quebec City Non Squamous Non Small Cell Lung Cancer Nsclc in Hamilton Non Squamous Non Small Cell Lung Cancer Nsclc in Kitchener Non Squamous Non Small Cell Lung Cancer Nsclc in London Non Squamous Non Small Cell Lung Cancer Nsclc in Halifax Non Squamous Non Small Cell Lung Cancer Nsclc in New York Non Squamous Non Small Cell Lung Cancer Nsclc in Los Angeles Non Squamous Non Small Cell Lung Cancer Nsclc in Chicago Non Squamous Non Small Cell Lung Cancer Nsclc in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease